Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Coutelle O, Schiffmann LM, Liwschitz M, et al. Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours. Br J Cancer. 2015;112(3):495–503. doi:10.1038/bjc.2014.62925562438
   PubMedGoogle Scholar
• Ruggiero A, Villa CH, Holland JP, et al. Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. Int J Nanomedicine. 2010;5:783–802. doi:10.2147/IJN.S1330021042424
   PubMed Web of Science ®Google Scholar
• Loree JM, Sha A, Soleimani M, et al. Survival impact of CAPOX versus FOLFOX in the adjuvant treatment of stage III colon cancer. Clin Colorectal Cancer. 2018;17(2):156–163. doi:10.1016/j.clcc.2018.01.01029486916
   PubMedGoogle Scholar
• Martini G, Troiani T, Cardone C, et al. Present and future of metastatic colorectal cancer treatment: a review of new candidate targets. World J Gastroenterol. 2017;23(26):4675–4688. doi:10.3748/wjg.v23.i26.467528765689
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;17(2):79–92. doi:10.1038/nrc.2016.12628050011
   PubMed Web of Science ®Google Scholar
• Alushin GM, Lander GC, Kellogg EH, Zhang R, Baker D, Nogales E. High-resolution microtubule structures reveal the structural transitions in alphabeta-tubulin upon GTP hydrolysis. Cell. 2014;157(5):1117–1129. doi:10.1016/j.cell.2014.03.05324855948
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang C, Zhang S, et al. Kanglaite sensitizes colorectal cancer cells to Taxol via NF-kappaBeta inhibition and connexin 43 upregulation. Sci Rep. 2017;7(1):1280. doi:10.1038/s41598-017-01480-228455529
   PubMedGoogle Scholar
• Zou H, Li L, Garcia Carcedo I, Xu ZP, Monteiro M, Gu W. Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis. Int J Nanomedicine. 2016;11:1947–1958. doi:10.2147/IJN.S10074427226714
   PubMed Web of Science ®Google Scholar
• Lin R, Li H, Chen Y, et al. FOLFOX versus POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) as a first-line treatment in advanced gastric cancer (AGC): a multicenter, randomized phase II trial, FNF-004 trial. J Clin Oncol. 2019;37(4_suppl):6. doi:10.1200/JCO.2019.37.4_suppl.6
   Web of Science ®Google Scholar
• Lin R, Zhao S, Li H, Liu J, Fan N. A phase II Study of FOLFOX versus POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel) plus FOLFOX as a first-line treatment in advanced gastric cancer (AGC): a feasibility analysis. J Clin Oncol. 2017;35(4_suppl):56. doi:10.1200/JCO.2016.69.137828034064
   PubMedGoogle Scholar
• Hassan MS, Awasthi N, Li J, et al. Superior therapeutic efficacy of nanoparticle albumin bound paclitaxel over cremophor-bound paclitaxel in experimental esophageal adenocarcinoma. Transl Oncol. 2018;11(2):426–435. doi:10.1016/j.tranon.2018.01.02229475139
   PubMedGoogle Scholar
• Alves RC, Fernandes RP, Eloy JO, Salgado HRN, Chorilli M. Characteristics, properties and analytical methods of paclitaxel: a review. Crit Rev Anal Chem. 2018;48(2):110–118. doi:10.1080/10408347.2017.141628329239659
   PubMed Web of Science ®Google Scholar
• Choudhury H, Gorain B, Tekade RK, Pandey M, Karmakar S, Pal TK. Safety against nephrotoxicity in paclitaxel treatment: oral nanocarrier as an effective tool in preclinical evaluation with marked in vivo antitumor activity. Regul Toxicol Pharmacol. 2017;91:179–189. doi:10.1016/j.yrtph.2017.10.02329080846
   PubMed Web of Science ®Google Scholar
• Wang F, Porter M, Konstantopoulos A, Zhang P, Cui H. Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy. J Control Release. 2017;267:100–118. doi:10.1016/j.jconrel.2017.09.02628958854
   PubMed Web of Science ®Google Scholar
• Cui X, Fan Q, Shi S, et al. A Novel Near-infrared Nanomaterial with high quantum efficiency and its applications in Real Time in-Vivo imaging. Nanotechnology. 2018;29:205705. doi:10.1088/1361-6528/aab2fa29488904
   PubMedGoogle Scholar
• Ma J, Wu H, Li Y, et al. Novel core-interlayer-shell DOX/ZnPc co-loaded MSNs@ pH-sensitive CaP@PEGylated liposome for enhanced synergetic chemo-photodynamic therapy. Pharm Res. 2018;35(3):57. doi:10.1007/s11095-017-2295-z29423532
   PubMedGoogle Scholar
• Wu D, Si M, Xue HY, Wong HL. Nanomedicine applications in the treatment of breast cancer: current state of the art. Int J Nanomedicine. 2017;12:5879–5892. doi:10.2147/IJN.S12343728860754
   PubMed Web of Science ®Google Scholar
• Tietjen GT, Saltzman WM. Nanomedicine gets personal. Sci Transl Med. 2015;7(314):314fs347. doi:10.1126/scitranslmed.aad3106
   Web of Science ®Google Scholar
• Danhier F. To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release. 2016;244(Pt A):108–121. doi:10.1016/j.jconrel.2016.11.01527871992
   PubMedGoogle Scholar
• Zhu L, Zhao H, Zhou Z, et al. Peptide-functionalized phase-transformation nanoparticles for low intensity focused ultrasound-assisted tumor imaging and therapy. Nano Lett. 2018;18:1831–1841.29419305
   PubMed Web of Science ®Google Scholar
• Sharma S, Mann AP, Molder T, et al. Vascular changes in tumors resistant to a vascular disrupting nanoparticle treatment. J Control Release. 2017;268:49–56. doi:10.1016/j.jconrel.2017.10.00629030222
   PubMedGoogle Scholar
• Wang T, Wang D, Liu J, et al. Acidity-triggered ligand-presenting nanoparticles to overcome sequential drug delivery barriers to tumors. Nano Lett. 2017;17(9):5429–5436. doi:10.1021/acs.nanolett.7b0203128753017
   PubMedGoogle Scholar
• Ma L, Chen Q, Ma P, et al. iRGD-functionalized PEGylated nanoparticles for enhanced colon tumor accumulation and targeted drug delivery. Nanomedicine. 2017;12(16):1991–2006. doi:10.2217/nnm-2017-010728745123
   PubMedGoogle Scholar
• Liu C, Yao S, Li X, Wang F, Jiang Y. iRGD-mediated core-shell nanoparticles loading carmustine and O(6)-benzylguanine for glioma therapy. J Drug Target. 2017;25(3):235–246. doi:10.1080/1061186X.2016.123809127646474
   PubMed Web of Science ®Google Scholar
• Yu H, Tang Z, Song W, Zhang D, Zhang Y, Chen X. Co-administration of iRGD enhancing the anticancer efficacy of cisplatin-loaded polypeptide nanoparticles. J Control Release. 2015;213:e145–e146. doi:10.1016/j.jconrel.2015.05.246
   PubMed Web of Science ®Google Scholar
• Zhang WQ, Yu KF, Zhong T, et al. Does ligand-receptor mediated competitive effect or penetrating effect of iRGD peptide when co-administration with iRGD-modified SSL? J Drug Target. 2015;23(10):897–909. doi:10.3109/1061186X.2015.103427926087869
   PubMed Web of Science ®Google Scholar
• Wang K, Zhang X, Liu Y, Liu C, Jiang B, Jiang Y. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates. Biomaterials. 2014;35(30):8735–8747. doi:10.1016/j.biomaterials.2014.06.04225023394
   PubMed Web of Science ®Google Scholar
• Li X, Jiang X. Microfluidics for producing poly (lactic-co-glycolic acid)-based pharmaceutical nanoparticles. Adv Drug Deliv Rev. 2018;128:101–114. doi:10.1016/j.addr.2017.12.01529277543
   PubMed Web of Science ®Google Scholar
• Xu B, Jin Q, Zeng J, et al. Combined tumor- and neovascular-”dual targeting” gene/chemo-therapy suppresses tumor growth and angiogenesis. ACS Appl Mater Interfaces. 2016;8(39):25753–25769. doi:10.1021/acsami.6b0860327615739
   PubMedGoogle Scholar
• Zeng X, Tao W, Mei L, Huang L, Tan C, Feng SS. Cholic acid-functionalized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer. Biomaterials. 2013;34(25):6058–6067. doi:10.1016/j.biomaterials.2013.04.05223694904
   PubMed Web of Science ®Google Scholar
• Abouelmagd SA, Sun B, Chang AC, Ku YJ, Yeo Y. Release kinetics study of poorly water-soluble drugs from nanoparticles: are we doing it right? Mol Pharm. 2015;12(3):997–1003. doi:10.1021/mp500817h25658769
   PubMed Web of Science ®Google Scholar
• Vinci M, Gowan S, Boxall F, et al. Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol. 2012;10:29. doi:10.1186/1741-7007-10-2922439642
   PubMed Web of Science ®Google Scholar
• Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm. 2008;69(1):1–9. doi:10.1016/j.ejpb.2007.08.00117826969
   PubMed Web of Science ®Google Scholar
• Aftab S, Shah A, Nadhman A, et al. Nanomedicine: an effective tool in cancer therapy. Int J Pharm. 2018;540(1–2):132–149. doi:10.1016/j.ijpharm.2018.02.00729427746
   PubMed Web of Science ®Google Scholar
• Kreuter J. Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Adv Drug Deliv Rev. 2014;71:2–14. doi:10.1016/j.addr.2013.08.00823981489
   PubMed Web of Science ®Google Scholar
• Huang Y, Fan CQ, Dong H, Wang SM, Yang XC, Yang SM. Current applications and future prospects of nanomaterials in tumor therapy. Int J Nanomedicine. 2017;12:1815–1825. doi:10.2147/IJN.S12734928331307
   PubMed Web of Science ®Google Scholar
• Simon-Gracia L, Hunt H, Scodeller P, et al. iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes. Biomaterials. 2016;104:247–257. doi:10.1016/j.biomaterials.2016.07.02327472162
   PubMed Web of Science ®Google Scholar
• Yan F, Wu H, Liu H, et al. Molecular imaging-guided photothermal/photodynamic therapy against tumor by iRGD-modified indocyanine green nanoparticles. J Control Release. 2016;224:217–228. doi:10.1016/j.jconrel.2015.12.05026739551
   PubMed Web of Science ®Google Scholar
• Gu G, Gao X, Hu Q, et al. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells. Biomaterials. 2013;34(21):5138–5148. doi:10.1016/j.biomaterials.2013.03.03623582684
   PubMed Web of Science ®Google Scholar
• Kaiser J. Mixed results from cancer replications unsettle field. Science (New York, NY). 2017;355(6322):234–235. doi:10.1126/science.355.6322.234
   Google Scholar
• Yao VJ, Ozawa MG, Varner AS, et al. Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels. Cancer Res. 2006;66(5):2639–2649. doi:10.1158/0008-5472.CAN-05-182416510583
   PubMed Web of Science ®Google Scholar
• Parsons-Wingerter P, Kasman IM, Norberg S, et al. Uniform overexpression and rapid accessibility of alpha5beta1 integrin on blood vessels in tumors. Am J Pathol. 2005;167(1):193–211. doi:10.1016/s0002-9440(10)62965-315972964
   PubMed Web of Science ®Google Scholar
• Majumder P, Bhunia S, Bhattacharyya J, Chaudhuri A. Inhibiting tumor growth by targeting liposomally encapsulated CDC20siRNA to tumor vasculature: therapeutic RNA interference. J Control Release. 2014;180:100–108. doi:10.1016/j.jconrel.2014.02.01224556418
   PubMed Web of Science ®Google Scholar
• Pang HB, Braun GB, Friman T, et al. An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability. Nat Commun. 2014;5:4904. doi:10.1038/ncomms597225277522
   PubMedGoogle Scholar
• Liu X, Lin P, Perrett I, et al. Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer. J Clin Invest. 2017;127(5):2007–2018. doi:10.1172/JCI9228428414297
   PubMed Web of Science ®Google Scholar